August 10, 2014 | VBL Therapeutics announced the termination of its underwriting agreement for its NASDAQ IPO by its underwriters Deutsche Bank and Wells Fargo Securities. According to Globe Newswire, the company was forced to terminate its IPO after an unnamed US shareholder did not fund payment shares it previously had agreed to purchase for the offering. As a result, no shares will be offered up in the IPO bid that went into effect on July 30, 2014. VBL Therapeutics is an Israeli clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

AI Startup Helps Doctors Analyze Heart Scans
February 08, 2023

AI Monitors High-Speed Conveyor Belts For Defects
February 08, 2023

Israel Hi-Tech Group In Rescue Mission To Turkey
February 08, 2023

Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023
Facebook comments